BioNTech
BioNTech, Roche's Bespoke Pancreatic Cancer Vaccine Demonstrates Lasting Responses in Early Trial
Premium
Patients had longer recurrence-free survival when they responded to autogene cevumeran, a mRNA vaccine designed to target up to 20 tumor-specific neoantigens.
In Brief This Week: BioNTech, Duality Biologics, Quest Diagnostics, Myriad Genetics, UCLA
News items for the week of Jan. 29, 2024.
BioNTech, Duality Biologics Begin Pivotal Phase III ADC Trial in Advanced HER2-Low Breast Cancer
The randomized trial pits the firms' jointly developed antibody-drug conjugate, BNT323/DB-1303, against standard-of-care chemotherapy.
The Swiss biotech is developing a personalized neoantigen vaccine and working with the NCI to test the ability of an off-the-shelf vaccine to prevent cancer in those with Lynch syndrome.
BioNTech to Study mRNA Cancer Vaccine as Adjuvant Pancreatic Cancer Treatment in Phase II Trial
The firm will evaluate its vaccine candidate autogene cevumeran plus Genentech's Tecentriq and chemo against standard-of-care adjuvant chemo alone.